Guilin Sanjin Pharmaceutical Co Ltd
Guilin Sanjin Pharmaceutical Co., Ltd. engages in the research, production, and sale of traditional Chinese and natural medicines in China and internationally. The company offers three gold particles, Guilin watermelon frost, watermelon frost lozenges, throat clearing spray, Naomaitai capsules, vertigo tablets, Xuanyunning granules, Gejie dingchuan capsule, compound panax notoginseng stomachache … Read more
Guilin Sanjin Pharmaceutical Co Ltd - Asset Resilience Ratio
Guilin Sanjin Pharmaceutical Co Ltd (002275) has an Asset Resilience Ratio of 14.80% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2010–2024)
This chart shows how Guilin Sanjin Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Guilin Sanjin Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥636.30 Million | 14.8% |
| Total Liquid Assets | CN¥636.30 Million | 14.80% |
Asset Resilience Insights
- Moderate Liquidity: Guilin Sanjin Pharmaceutical Co Ltd has 14.80% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Guilin Sanjin Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio
Compare Guilin Sanjin Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF |
Drug Manufacturers - Specialty & Generic | -0.02% |
|
Kamada
NASDAQ:KMDA |
Drug Manufacturers - Specialty & Generic | 21.63% |
|
Dongwha Pharm.Co.Ltd
KO:000020 |
Drug Manufacturers - Specialty & Generic | 1.92% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.46% |
|
Yuhan Corp.
KO:000100 |
Drug Manufacturers - Specialty & Generic | 0.99% |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153 |
Drug Manufacturers - Specialty & Generic | 1.81% |
|
Kotra Industries Bhd
KLSE:0002 |
Drug Manufacturers - Specialty & Generic | 9.82% |
|
Yuyu Pharma Inc
KO:000227 |
Drug Manufacturers - Specialty & Generic | 1.74% |
Annual Asset Resilience Ratio for Guilin Sanjin Pharmaceutical Co Ltd (2010–2024)
The table below shows the annual Asset Resilience Ratio data for Guilin Sanjin Pharmaceutical Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 14.79% | CN¥626.15 Million | CN¥4.23 Billion | +7.05pp |
| 2023-12-31 | 7.74% | CN¥304.69 Million | CN¥3.94 Billion | +3.67pp |
| 2022-12-31 | 4.07% | CN¥161.24 Million | CN¥3.96 Billion | -1.35pp |
| 2021-12-31 | 5.41% | CN¥221.77 Million | CN¥4.10 Billion | -3.74pp |
| 2020-12-31 | 9.15% | CN¥355.34 Million | CN¥3.88 Billion | +7.18pp |
| 2019-12-31 | 1.98% | CN¥67.50 Million | CN¥3.42 Billion | +1.98pp |
| 2018-12-31 | 0.00% | CN¥1.27K | CN¥3.41 Billion | -11.29pp |
| 2017-12-31 | 11.29% | CN¥364.60 Million | CN¥3.23 Billion | +3.95pp |
| 2016-12-31 | 7.34% | CN¥210.66 Million | CN¥2.87 Billion | +3.51pp |
| 2015-12-31 | 3.83% | CN¥105.60 Million | CN¥2.76 Billion | -5.15pp |
| 2014-12-31 | 8.98% | CN¥250.00 Million | CN¥2.78 Billion | +8.80pp |
| 2010-12-31 | 0.18% | CN¥3.60 Million | CN¥1.98 Billion | -- |